Checkpoint inhibition therapy involves the use of specific monoclonal antibodies, namely, anti-CTLA-4 [114], anti-PD-1 [115], and anti-PD-L1 antibodies [116], which bind to the immune checkpoint proteins of T cells to remove the inhibition of T cell function by tumor cells [117]. This evidence concerns the gene PDCD1 and neoplasm.